TNSN04121A1 - Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia - Google Patents

Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia

Info

Publication number
TNSN04121A1
TNSN04121A1 TNP2004000121A TNSN04121A TNSN04121A1 TN SN04121 A1 TNSN04121 A1 TN SN04121A1 TN P2004000121 A TNP2004000121 A TN P2004000121A TN SN04121 A TNSN04121 A TN SN04121A TN SN04121 A1 TNSN04121 A1 TN SN04121A1
Authority
TN
Tunisia
Prior art keywords
alkoxypropanoiques
inhibiteurs
tafia
acides
servant
Prior art date
Application number
TNP2004000121A
Other languages
English (en)
Inventor
Charlotte Moira Norfor Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN04121A1 publication Critical patent/TNSN04121A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2004000121A 2002-01-22 2004-06-30 Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia TNSN04121A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids
PCT/IB2003/000060 WO2003061652A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Publications (1)

Publication Number Publication Date
TNSN04121A1 true TNSN04121A1 (en) 2006-06-01

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000121A TNSN04121A1 (en) 2002-01-22 2004-06-30 Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia

Country Status (24)

Country Link
EP (1) EP1467731A1 (zh)
JP (1) JP2005520811A (zh)
KR (1) KR20040077775A (zh)
CN (1) CN1620291A (zh)
AP (1) AP2004003084A0 (zh)
AR (1) AR038197A1 (zh)
BR (1) BR0307016A (zh)
CA (1) CA2472238A1 (zh)
EA (1) EA200400716A1 (zh)
EC (1) ECSP045200A (zh)
HR (1) HRP20040659A2 (zh)
IL (1) IL162677A0 (zh)
IS (1) IS7310A (zh)
MA (1) MA27167A1 (zh)
MX (1) MXPA04006573A (zh)
NO (1) NO20043457L (zh)
OA (1) OA12756A (zh)
PA (1) PA8563501A1 (zh)
PE (1) PE20030929A1 (zh)
PL (1) PL371487A1 (zh)
TN (1) TNSN04121A1 (zh)
TW (1) TW200302094A (zh)
UY (1) UY27615A1 (zh)
WO (1) WO2003061652A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
WO2010065717A1 (en) * 2008-12-05 2010-06-10 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
DK2548871T3 (da) 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
JP5778133B2 (ja) * 2010-03-18 2015-09-16 第一三共株式会社 シクロプロパンカルボン酸誘導体
MX2015016961A (es) 2013-06-10 2016-04-25 Sanofi Sa Derivados de urea macrociclicos como inhibidores de tafia, su preparacion y su uso como productos farmaceuticos.
JPWO2017170460A1 (ja) 2016-03-29 2019-02-07 第一三共株式会社 炎症性腸疾患治療剤
CA3075892C (en) 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
EA005532B1 (ru) * 2000-08-17 2005-04-28 Пфайзер Инк. Замещенные имидазолы в качестве ингибиторов активированной формы активируемого тромбином ингибитора фибринолиза (tafia)

Also Published As

Publication number Publication date
EP1467731A1 (en) 2004-10-20
CN1620291A (zh) 2005-05-25
CA2472238A1 (en) 2003-07-31
AP2004003084A0 (en) 2004-09-30
PA8563501A1 (es) 2004-08-31
PE20030929A1 (es) 2003-11-05
AR038197A1 (es) 2005-01-05
MA27167A1 (fr) 2005-01-03
BR0307016A (pt) 2004-11-03
WO2003061652A1 (en) 2003-07-31
EA200400716A1 (ru) 2004-12-30
WO2003061652A8 (en) 2004-09-10
OA12756A (en) 2006-07-03
JP2005520811A (ja) 2005-07-14
MXPA04006573A (es) 2004-10-04
NO20043457L (no) 2004-08-19
UY27615A1 (es) 2003-08-29
PL371487A1 (en) 2005-06-13
IL162677A0 (en) 2005-11-20
ECSP045200A (es) 2004-08-27
HRP20040659A2 (en) 2004-10-31
IS7310A (is) 2004-06-14
TW200302094A (en) 2003-08-01
KR20040077775A (ko) 2004-09-06

Similar Documents

Publication Publication Date Title
BR0013237A (pt) Fenil oxazolidinonas substituìdas heterobiciclicas antibacterianas
RS20060143A (en) Phenyl or pyridil amide compounds as prostaglandin e2 antagonists
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
CY1108409T1 (el) Υβριδικα αντιβιοτικα οξαζολιδινονης-κινολονης
DE60024651D1 (de) Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
ATE427300T1 (de) Heterocyclisch substituierte amide als calpainhemmer
NO20064418L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
IL148903A0 (en) Certain alkylene diamine-substituted heterocycles
MY142807A (en) Benzimidazole derivative and use thereof.
CA2325741A1 (en) Urea derivatives having tnf- .alpha. production inhibitory effects
IN2012DN00758A (zh)
TNSN04121A1 (en) Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
MXPA04005940A (es) Acidos 3-(imidazolil)-2-aminopropanoicos.
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
ATE449773T1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
DE60124717D1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
TR200002485T2 (tr) N-Sülfonil ve N-Sülfinil Fenilglisinamid
TR200003877T2 (tr) İnsan CD23 üretiminin ve TNF salınmasının ihhibitörleri olan hiydroxamic acid türevleri
DE69808326D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
NO20020886L (no) Nye integrin- <alfa>v<beta>3-inhibitorer
DOP2003000564A (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos
TW200510300A (en) Amino alcohol compounds